T Metsvaht1, M-L Ilmoja1, Ü Parm1, L Maipuu1, M Merila1, I Lutsar1. 1. Paediatric Intensive Care Unit, Clinic of Anaesthesiology and Intensive Care, Tartu University Clinics, Tartu, EstoniaPaediatric Intensive Care Unit, Tallinn Children's Hospital, Tallinn, EstoniaInstitute of Microbiology, Tartu University, Tartu, EstoniaDepartment of Paediatrics, Tartu University Clinics, Tartu, Estonia.
Abstract
AIM: We aimed to compare the clinical efficacy of ampicillin (AMP) vs. penicillin (PEN) both combined with gentamicin in the empirical treatment of neonates at risk of early onset neonatal sepsis (EOS). METHODS: We performed an open label cluster randomized equivalence study in both Estonian neonatal intensive care units, including neonates with suspected EOS, aged less than 72 h. Primary end-point was clinical failure rate, expressed by need for change of antibiotic regimen within 72 h and/or 7-day all cause mortality. Bowel colonization was followed with biweekly perineal swab cultures. RESULTS:Incidence of proven EOS was 4.9%. Among neonates receiving AMP (n = 142) orPEN (n = 141) change of antibiotic regimen within 72 h (10/142 vs. 10/141; OR 1.02; 95% CI 0.40-2.59), 7-day mortality (11/142 vs. 14/141; OR 0.76; 95% CI 0.33-1.75) and over-all treatment failure (20/142 vs. 20/141; OR 1.01; 95% CI 0.52-1.97) occurred at similar rates. The only differences in gut colonization were lower number of patients colonised with enterococci, S. aureus and AMP resistant Acinetobacter spp. in AMP and lower number of those with S. haemolyticus and S. hominis in PEN arm. CONCLUSIONS: AMP and PEN combined with gentamicin have similar effectiveness in the empiric treatment of suspected neonatal EOS.
RCT Entities:
AIM: We aimed to compare the clinical efficacy of ampicillin (AMP) vs. penicillin (PEN) both combined with gentamicin in the empirical treatment of neonates at risk of early onset neonatal sepsis (EOS). METHODS: We performed an open label cluster randomized equivalence study in both Estonian neonatal intensive care units, including neonates with suspected EOS, aged less than 72 h. Primary end-point was clinical failure rate, expressed by need for change of antibiotic regimen within 72 h and/or 7-day all cause mortality. Bowel colonization was followed with biweekly perineal swab cultures. RESULTS: Incidence of proven EOS was 4.9%. Among neonates receiving AMP (n = 142) or PEN (n = 141) change of antibiotic regimen within 72 h (10/142 vs. 10/141; OR 1.02; 95% CI 0.40-2.59), 7-day mortality (11/142 vs. 14/141; OR 0.76; 95% CI 0.33-1.75) and over-all treatment failure (20/142 vs. 20/141; OR 1.01; 95% CI 0.52-1.97) occurred at similar rates. The only differences in gut colonization were lower number of patients colonised with enterococci, S. aureus and AMP resistant Acinetobacter spp. in AMP and lower number of those with S. haemolyticus and S. hominis in PEN arm. CONCLUSIONS:AMP and PEN combined with gentamicin have similar effectiveness in the empiric treatment of suspected neonatal EOS.
Authors: U Parm; T Metsvaht; E Sepp; M-L Ilmoja; H Pisarev; M Pauskar; I Lutsar Journal: Eur J Clin Microbiol Infect Dis Date: 2010-05-06 Impact factor: 3.267
Authors: Scott L Weiss; Mark J Peters; Waleed Alhazzani; Michael S D Agus; Heidi R Flori; David P Inwald; Simon Nadel; Luregn J Schlapbach; Robert C Tasker; Andrew C Argent; Joe Brierley; Joseph Carcillo; Enitan D Carrol; Christopher L Carroll; Ira M Cheifetz; Karen Choong; Jeffry J Cies; Andrea T Cruz; Daniele De Luca; Akash Deep; Saul N Faust; Claudio Flauzino De Oliveira; Mark W Hall; Paul Ishimine; Etienne Javouhey; Koen F M Joosten; Poonam Joshi; Oliver Karam; Martin C J Kneyber; Joris Lemson; Graeme MacLaren; Nilesh M Mehta; Morten Hylander Møller; Christopher J L Newth; Trung C Nguyen; Akira Nishisaki; Mark E Nunnally; Margaret M Parker; Raina M Paul; Adrienne G Randolph; Suchitra Ranjit; Lewis H Romer; Halden F Scott; Lyvonne N Tume; Judy T Verger; Eric A Williams; Joshua Wolf; Hector R Wong; Jerry J Zimmerman; Niranjan Kissoon; Pierre Tissieres Journal: Intensive Care Med Date: 2020-02 Impact factor: 17.440
Authors: Helgi Padari; Tuuli Metsvaht; Eva Germovsek; Charlotte I Barker; Karin Kipper; Koit Herodes; Joseph F Standing; Kersti Oselin; Tõnis Tasa; Hiie Soeorg; Irja Lutsar Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Joshua T Thaden; Jessica E Ericson; Heather Cross; Stephen P Bergin; Julia A Messina; Vance G Fowler; Daniel K Benjamin; Reese H Clark; Christoph P Hornik; P Brian Smith Journal: Pediatr Infect Dis J Date: 2015-11 Impact factor: 3.806
Authors: Christoph P Hornik; Daniel K Benjamin; P Brian Smith; Michael J Pencina; Adriana H Tremoulet; Edmund V Capparelli; Jessica E Ericson; Reese H Clark; Michael Cohen-Wolkowiez Journal: J Pediatr Date: 2016-08-10 Impact factor: 6.314